|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
ATE97498T1
(de)
|
1984-01-30 |
1993-12-15 |
Imp Cancer Res Tech |
Verbesserungen an wachstumsfaktoren.
|
|
US5401638A
(en)
|
1986-06-04 |
1995-03-28 |
Oncogene Science, Inc. |
Detection and quantification of neu related proteins in the biological fluids of humans
|
|
US4968603A
(en)
|
1986-12-31 |
1990-11-06 |
The Regents Of The University Of California |
Determination of status in neoplastic disease
|
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
DE69031120T2
(de)
|
1989-05-19 |
1998-01-15 |
Genentech, Inc., South San Francisco, Calif. |
Her2 extrazellulare domäne
|
|
DE68926248T2
(de)
|
1989-09-29 |
1996-12-19 |
Oncogene Science Inc |
p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
|
|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
|
CA2226575C
(en)
|
1995-07-27 |
2011-10-18 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
|
EP0950067B1
(en)
|
1996-11-27 |
2007-08-29 |
Genentech, Inc. |
Affinity purification of polypeptide on protein a matrix
|
|
US5994071A
(en)
|
1997-04-04 |
1999-11-30 |
Albany Medical College |
Assessment of prostate cancer
|
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
JP2002507404A
(ja)
|
1998-03-27 |
2002-03-12 |
ジェネンテク・インコーポレイテッド |
Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用
|
|
PT1308456E
(pt)
|
1998-05-06 |
2007-12-03 |
Genentech Inc |
Purificação de anticorpos por cromatografia de permuta iónica
|
|
US6573043B1
(en)
|
1998-10-07 |
2003-06-03 |
Genentech, Inc. |
Tissue analysis and kits therefor
|
|
JP5623681B2
(ja)
|
1999-05-14 |
2014-11-12 |
ジェネンテック， インコーポレイテッド |
抗−ＥｒｂＢ２抗体による治療
|
|
US20040013667A1
(en)
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US20030086924A1
(en)
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
IL147017A0
(en)
|
1999-06-25 |
2002-08-14 |
Genentech Inc |
TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
US6754305B1
(en)
|
1999-08-02 |
2004-06-22 |
Therma-Wave, Inc. |
Measurement of thin films and barrier layers on patterned wafers with X-ray reflectometry
|
|
TR200200472T2
(tr)
|
1999-08-27 |
2002-06-21 |
Genentech, Inc. |
Anti-Erb B2 antikorları ile tedavi için dozajlar
|
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
KR20130056201A
(ko)
|
2000-05-19 |
2013-05-29 |
제넨테크, 인크. |
ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
|
|
US6984494B2
(en)
|
2000-08-15 |
2006-01-10 |
Genentech, Inc. |
Analytical method
|
|
NZ526720A
(en)
|
2000-12-28 |
2007-11-30 |
Altus Pharmaceuticals Inc |
Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
|
|
US6695940B2
(en)
|
2001-04-05 |
2004-02-24 |
Alan D. Devoe |
Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
|
|
US20040048525A1
(en)
|
2002-01-28 |
2004-03-11 |
Sagucio Esteban N. |
Watercycle for wet rider
|
|
US7435797B2
(en)
|
2002-04-10 |
2008-10-14 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
|
US6982719B2
(en)
|
2002-07-15 |
2006-01-03 |
Sun Microsystems, Inc. |
Switching sample buffer context in response to sample requests for real-time sample filtering and video generation
|
|
ES2392525T3
(es)
|
2002-07-15 |
2012-12-11 |
F. Hoffmann-La Roche Ag |
Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
|
|
US7129840B2
(en)
|
2002-09-03 |
2006-10-31 |
Ricoh Company, Ltd. |
Document security system
|
|
JP2006516117A
(ja)
|
2002-11-21 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
|
|
EP1648940B1
(en)
|
2003-07-28 |
2016-04-27 |
Genentech, Inc. |
Reducing protein a leaching during protein a affinity chromatography
|
|
JP4969440B2
(ja)
|
2004-04-08 |
2012-07-04 |
デビッド， ビー． エイガス， |
疼痛治療のためのＥｒｂＢアンタゴニスト
|
|
US7195440B2
(en)
|
2004-05-27 |
2007-03-27 |
Lambert Charles F |
Agricultural silo auger system apparatus and method
|
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
SV2006002143A
(es)
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
|
KR20140032004A
(ko)
|
2004-07-22 |
2014-03-13 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
KR20070057839A
(ko)
|
2004-08-19 |
2007-06-07 |
제넨테크, 인크. |
변경된 이펙터 기능을 갖는 폴리펩티드 변이체
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
JP2008523073A
(ja)
|
2004-12-07 |
2008-07-03 |
ジェネンテック・インコーポレーテッド |
Ｈｅｒ阻害剤を用いた治療のための患者の選択
|
|
CA2592177A1
(en)
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of her antibodies
|
|
EP1850874B1
(en)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
|
WO2006096861A2
(en)
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
|
US20060212956A1
(en)
|
2005-03-14 |
2006-09-21 |
Genentech, Inc. |
Animal model of ligand activated HER2 expressing tumors
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
MY157955A
(en)
|
2005-07-06 |
2016-08-30 |
Hoffmann La Roche |
Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
US7700299B2
(en)
|
2005-08-12 |
2010-04-20 |
Hoffmann-La Roche Inc. |
Method for predicting the response to a treatment
|
|
CA2631981A1
(en)
|
2005-12-05 |
2007-06-14 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of binding partners
|
|
CA2636074A1
(en)
*
|
2006-01-04 |
2007-07-12 |
University Of Montpellier 1 |
Combination therapy using anti-egfr and anti-her2 antibodies
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
JP2009539836A
(ja)
|
2006-06-05 |
2009-11-19 |
ジェネンテック・インコーポレーテッド |
ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長
|
|
DK2056874T3
(da)
|
2006-08-21 |
2012-10-15 |
Hoffmann La Roche |
Tumorterapi med et anti-vegf-antistof
|
|
WO2008031531A1
(en)
*
|
2006-09-15 |
2008-03-20 |
F. Hoffmann-La Roche Ag |
Tumor therapy with a combination of anti-her2 antibodies
|
|
MX2009008981A
(es)
|
2007-03-02 |
2009-09-02 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her.
|
|
MX2009012838A
(es)
|
2007-06-06 |
2009-12-11 |
Hoffmann La Roche |
Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
|
|
EP2171090B1
(en)
|
2007-06-08 |
2013-04-03 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
|
AU2008298948B2
(en)
|
2007-09-12 |
2014-09-04 |
F. Hoffmann-La Roche Ag |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
CN101889025B
(zh)
|
2007-10-30 |
2013-11-13 |
健泰科生物技术公司 |
通过阳离子交换层析进行的抗体纯化
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
EP2260056A1
(en)
|
2008-03-06 |
2010-12-15 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
US9321842B2
(en)
*
|
2011-05-13 |
2016-04-26 |
Ganymed Pharmaceuticals Ag |
Antibodies for treatment of cancer
|
|
WO2013055874A2
(en)
*
|
2011-10-14 |
2013-04-18 |
Genentech, Inc. |
Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
|
|
RU2019115089A
(ru)
*
|
2013-04-16 |
2019-06-11 |
Дженентек, Инк. |
Варианты пертузумаба и их аналитическая характеристика
|
|
JP2017513901A
(ja)
*
|
2014-04-25 |
2017-06-01 |
ジェネンテック， インコーポレイテッド |
トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
|
|
US11186875B2
(en)
*
|
2015-06-12 |
2021-11-30 |
The Translational Genomics Research Institute |
Targeted therapies for cancer
|